Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.74 |
| ▸ | CCR3 | P51677 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7983823 | 0.98 | SIGMAR1 (0.72) | SIGMAR1CCR3CYP2D6MC4R | |
| SCHEMBL14761920 | 0.95 | SIGMAR1 (0.75) | SIGMAR1CCR3MC4R | |
| Hydrochloric Acid SCHEMBL9601328 | 0.93 | SIGMAR1 (0.73) | SIGMAR1CCR3MC4R | |
| Hydrochloric Acid SCHEMBL7982262 | 0.93 | SIGMAR1 (0.73) | SIGMAR1CCR3MC4R | |
| SCHEMBL249489 | 0.89 | SIGMAR1 (0.72) | SIGMAR1CCR3MC4R | |
| SCHEMBL6657455 | 0.88 | CCR3 (0.85) | SIGMAR1CCR3MC4R | |
| SCHEMBL6659913 | 0.88 | CCR3 (0.79) | SIGMAR1CCR3MC4R | |
| Hydrochloric Acid SCHEMBL23123378 | 0.87 | SIGMAR1 (0.69) | SIGMAR1CCR3MC4R | |
| Hydrochloric Acid SCHEMBL3449676 | 0.87 | SIGMAR1 (0.69) | SIGMAR1CCR3MC4R | |
| Hydrochloric Acid SCHEMBL10502885 | 0.86 | CCR3 (0.76) | SIGMAR1CCR3MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| CN-102918031-A | Radiolabeled compounds and methods thereof | GE HEALTHCARE LTD | 2013-02-06 | — | — | CN | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-4661481-A | Substituted phenylalkylhomopiperazinylpropyl(ureas or thioureas) useful for treatment of immulogical, inflammatory and allergic disorders | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0095029-B1 | 5-THIO-TETRAZOL COMPOUNDS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-11-05 | — | — | EP | disclosed |
| US-4585773-A | DIURETIC, HYPOTENSIVE | BRISTOL-MYERS COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4579947-A | Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1986-04-01 | — | — | US | disclosed |
| US-4563524-A | INTERMEDIATES FOR CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| EP-0029998-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-06 | — | — | EP | disclosed |
| EP-0129207-A2 | Substituted phenylalkyl(piperazinyl or homopiperazinyl)-propyl-(ureas or thioureas) | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4443443-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| EP-0095029-A1 | 5-Thio-tetrazol compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-30 | — | — | EP | disclosed |
| EP-0029998-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | SIGMAR1 1936/4885CCR3 35/4885CYP2D6 1253/4885 |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | SIGMAR1 71/4885CCR3 1323/4885CYP2D6 572/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | SIGMAR1 1936/4885CCR3 35/4885CYP2D6 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.